Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The tolerability of apatinib, an effective antiangiogenic agent, varies greatly in patients
with stage IV cancer during treatment. This study will include patients with advanced (stage
IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer, who
will be administered apatinib treatment starting from 250 mg Qd and closely monitored for
ADRs during the period of apatinib treatment. Meanwhile, relevant assay technologies will be
used to precisely detect changes of various biomarkers in the patients treated by apatinib,
with the aim of identifying biomarkers related to their prognosis and relevant complications
so as to screen out the favored population, establish the drug's indication(s) and reduce
relevant side effects.